Reveals superior bactericidal activity of an SL-Cu complex against certain bacteria, indicating its potential as an antibacterial agent.
In this study, a high-purity sophoroselipid-copper (SL-Cu) complex was synthesized using an improved method employing copper (II) acetate. Fourier transform infrared analysis of the purified SL-Cu complex revealed a distinctive absorption peak near 1,600 cm⁻¹. The bactericidal activity of the SL-Cu complex, at a copper (II) ion concentration of 1,000 µM and after incubation at 20°C for 30 min, exhibited a reduction greater than 4 log units against Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa. In contrast, its bactericidal activity against Enterococcus faecalis was comparatively lower, with a reduction of 0.90 log units. Furthermore, the SL-Cu complex demonstrated a statistically higher antibacterial efficacy against E. coli and S. aureus than CuSO₄ at the same copper (II) ion concentration. The bactericidal effect of the SL-Cu complex against E. coli was enhanced with increasing treatment temperatures between 15 and 40°C, consistently surpassing that of CuSO₄ across all tested temperatures. The inhibitory effects of bovine serum albumin, sodium chloride, EDTA-2Na, and 2,2 bipyridyl on the SL-Cu complex were restricted compared to those on CuSO₄, and in some experiments, these chemicals even enhanced its activity. These characteristics render the SL-Cu complex a promising antibacterial reagent. Flow cytometry analyses using fluorescent dyes suggested that the SL-Cu complex disrupted bacterial cell membranes and induced the generation of reactive oxygen species.
No takes yet. Share an insight, caveat, or question.
KUMASHITA et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: